BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wenz T, Williams SL, Bacman SR, Moraes CT. Emerging therapeutic approaches to mitochondrial diseases. Dev Disabil Res Rev 2010;16:219-29. [PMID: 20818736 DOI: 10.1002/ddrr.109] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kwak M, Ku M, Kang S. Inducible NAD(H)-linked methylglyoxal oxidoreductase regulates cellular methylglyoxal and pyruvate through enhanced activities of alcohol dehydrogenase and methylglyoxal-oxidizing enzymes in glutathione-depleted Candida albicans. Biochimica et Biophysica Acta (BBA) - General Subjects 2018;1862:18-39. [DOI: 10.1016/j.bbagen.2017.10.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
2 Scarpelli M, Todeschini A, Rinaldi F, Rota S, Padovani A, Filosto M. Strategies for treating mitochondrial disorders: An update. Molecular Genetics and Metabolism 2014;113:253-60. [DOI: 10.1016/j.ymgme.2014.09.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Kesner EE, Saada-Reich A, Lorberboum-Galski H. Characteristics of Mitochondrial Transformation into Human Cells. Sci Rep 2016;6:26057. [PMID: 27184109 DOI: 10.1038/srep26057] [Cited by in Crossref: 45] [Cited by in F6Publishing: 46] [Article Influence: 7.5] [Reference Citation Analysis]
4 Roestenberg P, Manjeri GR, Valsecchi F, Smeitink JA, Willems PH, Koopman WJ. Pharmacological targeting of mitochondrial complex I deficiency: the cellular level and beyond. Mitochondrion 2012;12:57-65. [PMID: 21757032 DOI: 10.1016/j.mito.2011.06.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
5 Cobley JN, Bartlett JD, Kayani A, Murray SW, Louhelainen J, Donovan T, Waldron S, Gregson W, Burniston JG, Morton JP, Close GL. PGC-1α transcriptional response and mitochondrial adaptation to acute exercise is maintained in skeletal muscle of sedentary elderly males. Biogerontology 2012;13:621-31. [PMID: 23187721 DOI: 10.1007/s10522-012-9408-1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
6 Meyerson C, Van Stavern G, McClelland C. Leber hereditary optic neuropathy: current perspectives. Clin Ophthalmol 2015;9:1165-76. [PMID: 26170609 DOI: 10.2147/OPTH.S62021] [Cited by in Crossref: 15] [Cited by in F6Publishing: 41] [Article Influence: 2.1] [Reference Citation Analysis]
7 Swerdlow RH. Bioenergetic medicine. Br J Pharmacol 2014;171:1854-69. [PMID: 24004341 DOI: 10.1111/bph.12394] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
8 La Morgia C, Carbonelli M, Barboni P, Sadun AA, Carelli V. Medical management of hereditary optic neuropathies. Front Neurol 2014;5:141. [PMID: 25132831 DOI: 10.3389/fneur.2014.00141] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
9 Breuer M, Koopman W, Koene S, Nooteboom M, Rodenburg R, Willems P, Smeitink J. The role of mitochondrial OXPHOS dysfunction in the development of neurologic diseases. Neurobiology of Disease 2013;51:27-34. [DOI: 10.1016/j.nbd.2012.03.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 5.9] [Reference Citation Analysis]
10 Bacman SR, Williams SL, Duan D, Moraes CT. Manipulation of mtDNA heteroplasmy in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. Gene Ther 2012;19:1101-6. [PMID: 22130448 DOI: 10.1038/gt.2011.196] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 4.5] [Reference Citation Analysis]
11 Erlich-Hadad T, Hadad R, Feldman A, Greif H, Lictenstein M, Lorberboum-Galski H. TAT-MTS-MCM fusion proteins reduce MMA levels and improve mitochondrial activity and liver function in MCM-deficient cells. J Cell Mol Med 2018;22:1601-13. [PMID: 29265583 DOI: 10.1111/jcmm.13435] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
12 Diaz F, Kotarsky H, Fellman V, Moraes CT. Mitochondrial disorders caused by mutations in respiratory chain assembly factors. Semin Fetal Neonatal Med 2011;16:197-204. [PMID: 21680271 DOI: 10.1016/j.siny.2011.05.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
13 Papadopoulou LC, Tsiftsoglou AS. Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders. Pharm Res 2011;28:2639-56. [PMID: 21874377 DOI: 10.1007/s11095-011-0546-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
14 Marín-garcía J. Methods to Study Mitochondrial Structure and Function. Mitochondria and Their Role in Cardiovascular Disease. Boston: Springer US; 2013. pp. 13-27. [DOI: 10.1007/978-1-4614-4599-9_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Branco AF, Ferreira A, Simões RF, Magalhães-novais S, Zehowski C, Cope E, Silva AM, Pereira D, Sardão VA, Cunha-oliveira T. Ketogenic diets: from cancer to mitochondrial diseases and beyond. Eur J Clin Invest 2016;46:285-98. [DOI: 10.1111/eci.12591] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 11.7] [Reference Citation Analysis]
16 Jurkute N, Harvey J, Yu-Wai-Man P. Treatment strategies for Leber hereditary optic neuropathy. Curr Opin Neurol 2019;32:99-104. [PMID: 30516647 DOI: 10.1097/WCO.0000000000000646] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
17 Van Bergen NJ, Chakrabarti R, O'Neill EC, Crowston JG, Trounce IA. Mitochondrial disorders and the eye. Eye Brain 2011;3:29-47. [PMID: 28539774 DOI: 10.2147/EB.S16192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
18 Karanjia R, Sadun AA. Advances in therapeutic strategies for Leber’s hereditary optic neuropathy. Expert Opinion on Orphan Drugs 2015;3:1439-46. [DOI: 10.1517/21678707.2015.1098531] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Carelli V, La Morgia C, Sadun AA. Mitochondrial dysfunction in optic neuropathies: animal models and therapeutic options. Current Opinion in Neurology 2013;26:52-8. [DOI: 10.1097/wco.0b013e32835c5f0b] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
20 Saada A. The use of individual patient's fibroblasts in the search for personalized treatment of nuclear encoded OXPHOS diseases. Mol Genet Metab 2011;104:39-47. [PMID: 21835663 DOI: 10.1016/j.ymgme.2011.07.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
21 Elstner M, Turnbull DM. Transcriptome analysis in mitochondrial disorders. Brain Research Bulletin 2012;88:285-93. [DOI: 10.1016/j.brainresbull.2011.07.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
22 Theodorou-Kanakari A, Karampitianis S, Karageorgou V, Kampourelli E, Kapasakis E, Theodossiadis P, Chatziralli I. Current and Emerging Treatment Modalities for Leber's Hereditary Optic Neuropathy: A Review of the Literature. Adv Ther 2018;35:1510-8. [PMID: 30173326 DOI: 10.1007/s12325-018-0776-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
23 Diaz F, Garcia S, Padgett KR, Moraes CT. A defect in the mitochondrial complex III, but not complex IV, triggers early ROS-dependent damage in defined brain regions. Hum Mol Genet 2012;21:5066-77. [PMID: 22914734 DOI: 10.1093/hmg/dds350] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 5.5] [Reference Citation Analysis]
24 Bacman SR, Williams SL, Pinto M, Moraes CT. The use of mitochondria-targeted endonucleases to manipulate mtDNA. Methods Enzymol 2014;547:373-97. [PMID: 25416366 DOI: 10.1016/B978-0-12-801415-8.00018-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
25 Silva DF, Selfridge JE, Lu J, E L, Cardoso SM, Swerdlow RH. Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention. Adv Pharmacol 2012;64:83-126. [PMID: 22840745 DOI: 10.1016/B978-0-12-394816-8.00003-9] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
26 Esmaeili MA, Yadav S, Gupta RK, Waggoner GR, Deloach A, Calingasan NY, Beal MF, Kiaei M. Preferential PPAR-α activation reduces neuroinflammation, and blocks neurodegeneration in vivo. Hum Mol Genet 2016;25:317-27. [PMID: 26604138 DOI: 10.1093/hmg/ddv477] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]